Pathology is becoming a more central part of biologically driven cancer trials, with a new perspective in the British Journal of Cancer arguing that specialist input should be built in earlier, before protocols, budgets and laboratory workflows are fixed. The article says that when studies depend on tumour material, biomarker-defined eligibility or mechanism-focused endpoints, pathology expertise is not just helpful but part of the trial architecture.
Why early pathology planning matters
The authors say pathology supports classification, staging, biomarker interpretation, eligibility assessment, response assessment and endpoint evaluation. They add that early involvement can improve feasibility, specimen governance, assay selection and quality assurance, while also increasing the long-term value of collected samples.
In practical terms, that means trial teams can better plan tissue acquisition, identify how much material is needed and reduce avoidable repeat procedures. The perspective also notes that this approach can help minimise screen failures caused by insufficient material and improve reproducibility across the timelines needed for recruitment, treatment allocation and go/no-go decisions.
A UK model already in place
The paper points to the Clinical Trials Pathology Advisory Group as a practical route for pre-submission specialist review in the UK. It says this guidance role is now within the Pathological Society of Great Britain and Ireland Clinical Trials Pathology Subcommittee, which was established in 2024 to continue and expand the agenda.
The authors argue that pathology should be visible before funding submission, when key decisions can still be changed. Their view is that for biologically rich cancer trials, early pathology planning should be treated as core infrastructure, linking the clinical question, the specimen pathway, the assay, the endpoint and the timing of trial decisions.
What this could mean for future studies
The perspective does not describe a single new treatment or test, but it does underline a broader shift in cancer research design. As trials become more dependent on molecular and tissue-based evidence, the paper suggests that embedding pathologists from the start may help studies run more efficiently and deliver more reliable results.
That message comes at a time when UK medical research organisations continue to back translational work across cancer and other diseases. The Medical Research Council’s recent news page, for example, highlights continuing support for research ranging from clinical careers to cancer-related studies.
Photo source: AI-generated or edited image
